Eluvia™ peripheral stent system for the treatment of peripheral lesions above the knee

References

• Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340.
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes. 2010;3:642–651.
   PubMed Web of Science ®Google Scholar
• Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57:1700–1708.
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
   PubMed Web of Science ®Google Scholar
• Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394–401.
   PubMed Web of Science ®Google Scholar
• Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
   PubMed Web of Science ®Google Scholar
• Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther. 2006;13(Suppl 2):II30–II40.
   PubMed Web of Science ®Google Scholar
• Fischer GM, Llaurado JG. Collagen and elastin content in canine arteries selected from functionally different vascular beds. Circ Res. 1966;19:394–399.
   PubMed Web of Science ®Google Scholar
• Davaine JM, Quillard T, Chatelais M, et al. Bone like arterial calcification in femoral atherosclerotic lesions: prevalence and role of osteoprotegerin and pericytes. Eur J Vasc Endovasc Surg. 2016;51:259–267.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Schömig A, Dietz R, et al. Time course of restenosis during the first year after emergency coronary stenting. Circulation. 1993;87:1498–1505.
   PubMed Web of Science ®Google Scholar
• Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749.
   PubMed Web of Science ®Google Scholar
• Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78:611–617.
   PubMed Web of Science ®Google Scholar
• Hou D, Huibregtse BA, Eppihimer MJ, et al. Fluorocopolymer-coated nitinol self-expanding low dose paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in porcine iliofemoral model. EuroIntervention. Forthcoming 2016.
   PubMedGoogle Scholar
• Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96(6):636–645.
   PubMed Web of Science ®Google Scholar
• Wiskirchen J, Schöber W, Schart N, et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004;39:565–571.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Takumi T, Mathew V, et al. Plaque characteristics and arterial remodeling in coronary and peripheral arterial systems. Atherosclerosis. 2012;223:365–371.
   PubMed Web of Science ®Google Scholar
• Zacharias SK, Safian RD, Madder RD, et al. Invasive evaluation of plaque morphology of symptomatic superficial femoral artery stenoses using combined near-infrared spectroscopy and intravascular ultrasound. Vasc Med. 2016;21:337–344.
   PubMed Web of Science ®Google Scholar
• Müller-Hülsbeck S, Keirse K, Zeller T, et al. Twelve month results from the MAJESTIC trial of the eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23(5):701–707.
   Web of Science ®Google Scholar
• Wilson GJ, Huibregtse BA, Stejskal EA, et al. Vascular response to a third generation everolimus-eluting stent. EuroIntervention. 2010;6:512–519.
   PubMed Web of Science ®Google Scholar
• Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, et al. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials. 2010;31:648–657.
   PubMed Web of Science ®Google Scholar
• Forrester JS, Fishbein M, Helfant R, et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758–769.
   PubMed Web of Science ®Google Scholar
• Kaluza G. Fluorocopolymer-coated Nitinol self-expanding Paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in porcine iliofemoral model. Leipzig: LINC; 2016.
   Google Scholar
• Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285–292.
   PubMed Web of Science ®Google Scholar
• Bosiers M, Deloose K, Callaert J, et al. 4-French-compatible endovascular material is safe and effective in the treatment of femoropopliteal occlusive disease: results of the 4-EVER trial. J Endovasc Ther. 2013;20:746–756.
   PubMed Web of Science ®Google Scholar
• Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1–9.
   PubMed Web of Science ®Google Scholar
• IDEV. Supera Peripheral Stent System SSED (SUPERB). 2014 [cited 2016 Apr 20]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120020b.pdf
   Google Scholar
• Laird JR, Jain A, Zeller T, et al. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the Complete SE multicenter trial. J Endovasc Ther. 2014;21:202–212.
   PubMed Web of Science ®Google Scholar
• Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261–269.
   PubMed Web of Science ®Google Scholar
• Cordis. SMART CONTROL SSED (STROLL). 2012 [cited 2016 Apr 20]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120002b.pdf
   Google Scholar
• Matsumura JS, Yamanouchi D, Goldstein JA, et al. The United States study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the protege everflex nitinol stent system II (DURABILITY II). J Vasc Surg. 2013;58(73––83):e71.
   Google Scholar
• Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18:613–623.
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–2427.
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver ptx randomized trial. Circulation. 2016;133:1472–1483.
   PubMed Web of Science ®Google Scholar
• Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
   PubMed Web of Science ®Google Scholar
• Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.
   PubMed Web of Science ®Google Scholar
• Micari A, Cioppa A, Vadalà G, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012;5:331–338.
   PubMed Web of Science ®Google Scholar
• Micari A, Cioppa A, Vadalà G, et al. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. JACC Cardiovasc Interv. 2013;6:282–289.
   PubMed Web of Science ®Google Scholar
• Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67.
   PubMed Web of Science ®Google Scholar
• Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–19.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Piorkowski M, Gorner H, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–724.
   PubMed Web of Science ®Google Scholar
• Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–840.
   PubMed Web of Science ®Google Scholar
• Zeller T, Rastan A, Macharzina R, et al. Novel approaches to the management of advanced peripheral artery disease: perspectives on drug-coated balloons, drug-eluting stents, and bioresorbable scaffolds. Curr Cardiol Rep. 2015;17:624.
   PubMed Web of Science ®Google Scholar